Share Name Share Symbol Market Type Share ISIN Share Description
Nuformix Plc LSE:NFX London Ordinary Share GB00BYW79Y38 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.025 1.52% 1.675 1.60 1.75 1.675 1.65 1.65 1,836,829 11:44:49
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Nonequity Investment Instruments 0.2 -1.4 -0.2 - 10

Nuformix PLC Letter to shareholders re: Dr Anne Brindley

22/07/2021 7:00am

RNS Non-Regulatory


Nuformix PLC

22 July 2021

REACH - Non-regulatory announcement

Nuformix plc

("Nuformix" or the "Company")

Letter to shareholders re: Dr Anne Brindley

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that further to the RNS issued yesterday on the departure of Dr Anne Brindley as CEO, the Company has issued a letter to shareholders. The letter can be viewed here:


 Nuformix plc                                                        via Walbrook 
 Dr Alastair Riddell, Non-Executive 
 Dr Anne Brindley, CEO 
 Allenby Capital Limited                                     +44 (0) 20 3328 5656 
 Nick Athanas / George Payne (Corporate 
 Stefano Aquilino / Matt Butlin (Sales 
  and Corporate Broking) 
 Walbrook PR                        or +44 (0)20 
                                                                       7933 87 80 
 Anna Dunphy / Paul McManus /                      Tel: +44 (0)7876 741 001 / +44 
  Kiki Zaccagnini                                                 (0)7980 541 893 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

For more information, please visit .

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

July 22, 2021 02:00 ET (06:00 GMT)

1 Year Nuformix Chart

1 Year Nuformix Chart

1 Month Nuformix Chart

1 Month Nuformix Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210725 17:04:15